免疫检查点阻断联合冷冻消融在免疫健全激素敏感前列腺癌小鼠模型中的研究
本研究在免疫健全激素敏感Myc-Cap前列腺癌小鼠模型中,探讨冷冻消融联合免疫检查点阻断的协同作用。结果显示抗CTLA-4抗体联合冷冻消融可延迟远端肿瘤生长并降低死亡率,且该协同依赖CD3+和CD8+细胞;而PD-1阻断联合冷冻消融未见优于单药,但三联疗法(雄激素剥夺+冷冻消融+PD-1阻断)可延长部分小鼠生存。
要点
- 抗CTLA-4联合冷冻消融延迟远端肿瘤生长14.8天并降低死亡率4倍
- 该协同效应依赖CD3+和CD8+ T细胞
- PD-1阻断联合冷冻消融未优于单药,但加用雄激素剥夺可增强效果
核心结论
- 冷冻消融联合低剂量抗CTLA-4阻断或三联疗法(雄激素剥夺+冷冻消融+PD-1阻断)可增强检查点阻断在前列腺癌中的效果。
研究设计与样本
- FVB/NJ小鼠双侧皮下接种1×10^6或0.2×10^6同源激素敏感Myc-Cap细胞建立同步移植瘤。
- 小鼠接受四次腹腔注射抗PD-1(10 mg/kg)、抗CTLA-4(1 mg/kg)或同型对照抗体,联合或不联合较大肿瘤移植瘤的冷冻消融,联合或不联合地加瑞克(degarelix)新辅助雄激素剥夺治疗(ADT)。
- 通过T细胞清除实验评估观察到的肿瘤学效应的免疫依赖性。
主要发现
- 与单用冷冻消融相比,抗CTLA-4抗体联合冷冻消融使远端肿瘤生长延迟14.8天(p=0.0006),死亡率降低4倍(p=0.0003)。
- 该协同作用依赖于CD3+和CD8+细胞。
- PD-1阻断联合冷冻消融未显示优于任一单药治疗的获益。
- 在抗PD-1治疗联合冷冻消融基础上加用ADT,使未治疗肿瘤加速生长的时间加倍(p=0.0021),并在25%的小鼠中延长生存(与冷冻消融联合ADT相比)。
- 抗PD-1联合ADT和冷冻消融对小鼠生存的影响可被T细胞清除所消除。
临床怎么用
- 局部冷冻消融可能作为增强前列腺癌免疫检查点阻断疗效的策略,尤其与抗CTLA-4或三联方案联合时。
局限性
- 本研究为小鼠模型临床前研究,结果需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer remains the second leading cause of cancer related death in men. Immune check point blocking antibodies have revolutionized treatment of multiple solid tumors, but results in prostate cancer remain marginal. Previous reports have suggested that local therapies, in particular cryoablation might increase tumor immunogenicity. In this work, we examine potential synergism between tumor cryoabalation and check point blocking antibodies. METHODS: FVB/NJ mice were injected subcutaneously into each flank with either 1 × 106 or 0.2 × 106 isogenic hormone sensitive Myc-Cap cells to establish synchronous grafts. Mice were treated with four intraperitoneal injections of anti-PD-1 (10 mg/kg), anti-CTLA-4 (1 mg/kg), or isotype control antibody with or without adjuvant cryoablation of the larger tumor graft and with or without neo-adjuvant androgen deprivation with degarelix (ADT). Mouse survival and growth rates of tumor grafts were measured. The immune dependency of observed oncological effects was evaluated by T cell depletion experiments. RESULTS: Treatment with anti-CTLA-4 antibody and cryoablation delayed the growth of the distant tumor by 14.8 days (p = 0.0006) and decreased the mortality rate by factor of 4 (p = 0.0003) when compared to cryoablation alone. This synergy was found to be dependent on CD3+ and CD8+ cells. Combining PD-1 blockade with cryoablation did not show a benefit over use of either treatment alone. Addition of ADT to anti-PD1 therapy and cryoablation doubled the time to accelerated growth in the untreated tumors (p = 0.0021) and extended survival when compared to cryoablation combined with ADT in 25% of the mice. Effects of combining anti-PD1 with ADT and cryoablation on mouse survival were obviated by T cell depletion. CONCLUSION: Trimodal therapy consisting of androgen deprivation, cryoablation and PD-1 blockade, as well as the combination of cryoablation and low dose anti-CTLA-4 blockade showed that local therapies with cryoablation could be considered to augment the effects of checkpoint blockade in prostate cancer.
引用
- Benzon B, Glavaris SA, Simons BW, et al. Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer. Prostate Cancer Prostatic Dis. 2018. PMID: 29556048. doi:10.1038/s41391-018-0035-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。